Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 10/20 | 0.44 |
| ▸ | CCND1 | P24385 | 10/20 | 0.44 |
| ▸ | CCND2 | P30279 | 10/20 | 0.44 |
| ▸ | CCND3 | P30281 | 10/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.44 |
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211567 | 0.86 | CYP1A2 (0.48) | CDK4CCND1CCND2CCND3CYP1A2 | |
| SCHEMBL12090783 | 0.81 | CDK4 (0.46) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL4135677 | 0.78 | MTNR1A (0.40) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL19212821 | 0.78 | CDK4 (0.43) | CDK4CCND1CCND2CCND3CCNB2 | |
| SCHEMBL4135768 | 0.76 | CYP1A2 (0.50) | CDK4CCND1CCND2CCND3CYP1A2 | |
| SCHEMBL19211574 | 0.76 | CDK4 (0.44) | CDK4CCND1CCND2CCND3CYP1A2 | |
| SCHEMBL19231463 | 0.76 | CYP1A2 (0.62) | CDK4CCND1CCND2CCND3CYP1A2 | |
| SCHEMBL19211612 | 0.76 | CYP1A2 (0.45) | CDK4CCND1CCND2CCND3CYP1A2 | |
| SCHEMBL3842971 | 0.74 | CYP1A2 (0.38) | CYP1A2TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL19212764 | 0.74 | BTK (0.43) | CDK4CCND1CCND2CCND3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179636-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2021-06-17 | — | — | US | disclosed |
| US-20190055266-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190040083-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2019-02-07 | — | — | US | disclosed |
| EP-3414245-A1 | ANTIBACTERIAL COMPOUNDS | Redx Pharma Plc (GB) | 2018-12-19 | — | — | EP | disclosed |
| EP-3413976-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2018-12-19 | — | — | EP | disclosed |
| EP-3414246-A1 | ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137743-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137742-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137744-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040083-A1 | ANTIBACTERIAL COMPOUNDS | OXA1L, SYMPK, TBCD | CDK4 485/4885CCND1 333/4885CCND2 326/4885 |
| US-20190055266-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | OXA1L, OGFOD1, OCIAD2 | CDK4 66/4885CCND1 476/4885CCND2 291/4885 |
| US-20210179636-A1 | ANTIBACTERIAL COMPOUNDS | OXA1L, SYMPK, TBCD | CDK4 485/4885CCND1 333/4885CCND2 326/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | CDK4 1317/4885CCND1 801/4885CCND2 1040/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | CDK4 1691/4885CCND1 1048/4885CCND2 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.